Leerink Swann Maintains Bullish Stance on Alnylam Pharmaceuticals (ANLY), Sees Dramatic Upside
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $147.70 --0%
Rating Summary:
24 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 5 | New: 40
Rating Summary:
24 Buy, 13 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 5 | Down: 5 | New: 40
Join SI Premium – FREE
Leerink Swann reiterated their Outperform rating and $25-$27 valuation rant on Alnylam Pharmaceuticals (NASDAQ: ALNY) Tuesday, saying there is growing phama interest and upside drivers.
The firm comments: "We reiterate our DCF-based $25-27 valuation driven by primarily by ALN-TTR-2 for TTR Amyloidosis and incrementally by ALN-PCS-02 for hypercholesterolemia. ALNY and Regulus (45% owned by ALNY) have been increasingly busy signing pipeline and business development partnerships, highlighting potential renewed and meaningful interest by large pharma. Regulus recently signed a deal with AZN (MP) and BIIB (OP) while ALNY today announced a partnership with Monsanto (MON, NR). After delivery advancements and solid ALN-PCS-02 proofof- concept (POC) data, we foresee this compound differentiating itself from other antibody approaches targeting PCS-K9 and drawing a large partnership near term."
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $17.74 yesterday.
The firm comments: "We reiterate our DCF-based $25-27 valuation driven by primarily by ALN-TTR-2 for TTR Amyloidosis and incrementally by ALN-PCS-02 for hypercholesterolemia. ALNY and Regulus (45% owned by ALNY) have been increasingly busy signing pipeline and business development partnerships, highlighting potential renewed and meaningful interest by large pharma. Regulus recently signed a deal with AZN (MP) and BIIB (OP) while ALNY today announced a partnership with Monsanto (MON, NR). After delivery advancements and solid ALN-PCS-02 proofof- concept (POC) data, we foresee this compound differentiating itself from other antibody approaches targeting PCS-K9 and drawing a large partnership near term."
For an analyst ratings summary and ratings history on Alnylam Pharmaceuticals click here. For more ratings news on Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $17.74 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Downgrades Hims and Hers (HIMS) to Hold
- Morgan Stanley Downgrades Integral Ad Science Holding Corp (IAS) to Equalweight
- Goldman Sachs Starts DraftKings Inc. (DKNG) at Buy, 'Inflecting Profitability as Unit Economics Improve'
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
